Interleukin-2 functions in anaplastic large cell lymphoma cells through augmentation of extracellular signal-regulated kinases 1/2 activation

International Journal of Biomedical Science

Volumn 7, Issue 3, 2011, Pages 181-190

  Ito, Masanori ^a   Zhao, Nianxi ^a   Zeng, Zihua ^a   Zhou, Xiaobo ^a   Chang, Chung Che ^a   Zu, Youli ^a  

^a HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

Anaplastic large cell lymphoma (ALCL); CD25 IL 2 receptor; Extracellular signal regulated kinases (ERK1 2); IL 2 signaling; Tumor microenvironment

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; INTERLEUKIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; CANCER CELL CULTURE; CASE REPORT; CELL FUNCTION; CELL GROWTH; CELL SURVIVAL; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 80054040021     PISSN: 15509702     EISSN: 15552810     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Herreros B, Sanchez-Aguilera A, Piris MA. Lymphoma microenvironment: culprit or innocent? Leukemia. 2008; 22: 49-58.
2. Sanchez-Beato M, Sanchez-Aguilera A, Piris MA. Cell cycle deregu - lation in B-cell lymphomas. Blood. 2003; 101: 1220-1235.
3. Wotherspoon AC, Doglioni C, Diss TC, Pan L, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993; 342: 575-577.
4. Hermine O, Lefrere F, Bronowicki JP, Mariette X, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N. Engl. J. Med. 2002; 347: 89-94.
5. Sagaert X, De Wolf-Peeters C, Noels H, Baens M. The pathogenesis of MALT lymphomas: where do we stand? Leukemia. 2007; 21: 389-396.
6. Burger JA, Burger M, Kipps TJ. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells. Blood. 1999; 94: 3658-3667.
7. Redondo-Munoz J, Escobar-Diaz E, Samaniego R, Terol MJ, et al. MMP-9 in B-cell chronic lymphocytic leukemia is up-regulated by alpha4beta1 integrin or CXCR4 engagement via distinct signaling pathways, localizes to podosomes, and is involved in cell invasion and migration. Blood. 2006; 108: 3143-3151.
8. Yurchenko M, Sidorenko SP. Hodgkin's lymphoma: the role of cell surface receptors in regulation of tumor cell fate. Exp. Oncol. 2010; 32: 214-223.
9. Gerber HP. Emerging immunotherapies targeting CD30 in Hodgkin's lymphoma. Biochem. Pharmacol. 2010; 79: 1544-1552.
10. Lamprecht B, Kreher S, Anagnostopoulos I, Johrens K, et al. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood. 2008; 112: 3339-3347.
11. Aldinucci D, Gloghini A, Pinto A, De Filippi R, et al. The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J. Pathol. 2010; 221: 248-263.
12. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002; 99: 4283-4297.
13. Corcione A, Ottonello L, Tortolina G, Facchetti P, et al. Stromal cellderived factor-1 as a chemoattractant for follicular center lymphoma B cells. J. Natl. Cancer Inst. 2000; 92: 628-635.
14. Husson H, Freedman AS, Cardoso AA, Schultze J, et al. CXCL13 (BCA-1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells. Br. J. Haematol. 2002; 119: 492-495.
15. Morris SW, Kirstein MN, Valentine MB, Dittmer KG, et al. Look AT: Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science. 1994; 263: 1281-1284.
16. Falini B, Pileri S, Zinzani PL, Carbone A, et al. ALK+ lymphoma: clinico-pathological findings and outcome. Blood. 1999; 93: 2697-2706.
17. Stein H, Foss HD, Durkop H, Marafioti T, et al. CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood. 2000; 96: 3681-3695.
18. Delsol G. The 2008 WHO lymphoma classification. Ann Pathol. 2008; 28 Spec No 1: S20-24
19. Wright CW, Rumble JM, Duckett CS. CD30 activates both the canonical and alternative NF-kappaB pathways in anaplastic large cell lymphoma cells. J. Biol. Chem. 2007; 282: 10252-10262.
20. Karasuyama H, Tohyama N, Tada T. Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. J. Exp. Med. 1989; 169: 13-25.
21. Watanabe M, Sasaki M, Itoh K, Higashihara M, et al. JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma. Cancer Res. 2005; 65: 7628-7634.
22. Teshigawara K, Wang HM, Kato K, Smith KA. Interleukin 2 highaffinity receptor expression requires two distinct binding proteins. J. Exp. Med. 1987; 165: 223-238.
23. Smith KA. The interleukin 2 receptor. Adv. Immunol. 1988; 42: 165-179
24. Theze J, Alzari PM, Bertoglio J. Interleukin 2 and its receptors: recent advances and new immunological functions. Immunol. Today. 1996; 17: 481-486.
25. Nelson BH, Willerford DM. Biology of the interleukin-2 receptor. Adv. Immunol. 1998; 70: 1-81.
26. Wang HM, Smith KA. The interleukin 2 receptor. Functional consequences of its bimolecular structure. J. Exp. Med. 1987; 166: 1055-1069.
27. Smith KA. Interleukin-2. Curr. Opin. Immunol. 1992; 4: 271-276.
28. Zhang Q, Nowak I, Vonderheid EC, Rook AH, et al. Activation of Jak/ STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA. 1996; 93: 9148-9153.
29. Wei S, Gamero AM, Liu JH, Daulton AA, et al. Control of lytic function by mitogen-activated protein kinase/extracellular regulatory kinase 2 (ERK2) in a human natural killer cell line: identification of perforin and granzyme B mobilization by functional ERK2. J. Exp. Med. 1998; 187: 1753-1765.
30. Gadina M, Sudarshan C, Visconti R, Zhou YJ, et al. The docking molecule gab2 is induced by lymphocyte activation and is involved in signaling by interleukin-2 and interleukin-15 but not other common gamma chain-using cytokines. J. Biol. Chem. 2000; 275: 26959-26966.
31. Rincon M, Flavell RA, Davis RJ. Signal transduction by MAP kinases in T lymphocytes. Oncogene. 2001; 20: 2490-2497.
32. Bessoles S, Fouret F, Dudal S, Besra GS, et al. IL-2 triggers specific signaling pathways in human NKT cells leading to the production of proand anti-inflammatory cytokines. J. Leukoc. Biol. 2008; 84: 224-33.
33. Inoue J, Seiki M, Taniguchi T, Tsuru S, et al. Induction of interleukin 2 receptor gene expression by p40x encoded by human T-cell leukemia virus type 1. Embo. J. 1986; 5: 2883-2888.
34. Cross SL, Feinberg MB, Wolf JB, Holbrook NJ, et al. Regulation of the human interleukin-2 receptor alpha chain promoter: activation of a nonfunctional promoter by the transactivator gene of HTLV-I. Cell. 1987; 49: 47-56.
35. Siekevitz M, Feinberg MB, Holbrook N, Wong-Staal F, et al. Activation of interleukin 2 and interleukin 2 receptor (Tac) promoter expression by the trans-activator (tat) gene product of human T-cell leukemia virus, type I. Proc. Natl. Acad. Sci. USA. 1987; 84: 5389-5393.
36. Ballard DW, Bohnlein E, Lowenthal JW, Wano Y, et al. HTLV-I tax induces cellular proteins that activate the kappa B element in the IL-2 receptor alpha gene. Science. 1988; 241: 1652-1655.
37. Leung K, Nabel GJ. HTLV-1 transactivator induces interleukin-2 receptor expression through an NF-kappa B-like factor. Nature. 1988; 333: 776-778.
38. Hattori T, Uchiyama T, Toibana T, Takatsuki K, et al. Surface phenotype of Japanese adult T-cell leukemia cells characterized by monoclonal antibodies. Blood. 1981; 58: 645-647.
39. Uchiyama T, Hori T, Tsudo M, Wano Y, et al. Interleukin-2 receptor (Tac antigen) expressed on adult T cell leukemia cells. J. Clin. Invest. 1985; 76: 446-453.
40. Waldmann TA. The IL-2/IL-2 receptor system: a target for rational immune intervention. Trends Pharmacol. Sci. 1993; 14: 159-164.
41. Yamada G, Kitamura Y, Sonoda H, Harada H, et al. Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. Embo. J. 1987; 6: 2705-2709.
42. Watson J. Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. J. Exp. Med. 1979; 150: 1510-1519.
43. Gootenberg JE, Ruscetti FW, Mier JW, Gazdar A, et al. Human cutaneous T cell lymphoma and leukemia cell lines produce and respond to T cell growth factor. J. Exp. Med. 1981; 154: 1403-1418.
44. Duprez V, Lenoir G, Dautry-Varsat A. Autocrine growth stimulation of a human T-cell lymphoma line by interleukin 2. Proc. Natl. Acad. Sci. USA. 1985; 82: 6932-6936.
45. Arima N, Daitoku Y, Ohgaki S, Fukumori J, et al. Autocrine growth of interleukin 2-producing leukemic cells in a patient with adult T cell leukemia. Blood. 1986; 68: 779-782.
46. Maruyama M, Shibuya H, Harada H, Hatakeyama M, et al. Evidence for aberrant activation of the interleukin-2 autocrine loop by HTLV1-encoded p40x and T3/Ti complex triggering. Cell. 1987; 48: 343-350.
47. Takashi S, Okubo Y, Horie S. Contribution of CD54 to human eosinophil and neutrophil superoxide production. J. Appl. Physiol. 2001; 91: 613-622.
48. Fischer P, Nacheva E, Mason DY, Sherrington PD, et al. A Ki-1 (CD30) positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood. 1988; 72: 234-240.
49. Morgan R, Smith SD, Hecht BK, Christy V, et al. Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5) (p23;q35) common to malignancies with features of so-called malignant histiocytosis. Blood. 1989; 73: 2155-2164.
50. Wellmann A, Thieblemont C, Pittaluga S, Sakai A, et al. Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood. 2000; 96: 398-404.
51. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, et al. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 1998; 273: 18623-18632.
52. Gillis S, Watson J: Biochemical and biological characterization of lymphocyte regulatory molecules. V. Identification of an interleukin 2-producing human leukemia T cell line. J. Exp. Med. 1980; 152: 17091719.
53. Ito M, Zhao N, Zeng Z, Chang CC, et al. In vitro synergistic inhibition of Anaplastic Large T-cell Lymphoma cells by combination of ALK gene silence and kinase inhibitor U0126. Cancer Gene Therapy. 2010; 17: 633-644
54. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature. 2001; 410: 37-40.
55. Zhang Y, Dong C. Regulatory mechanisms of mitogen-activated kinase signaling. Cell Mol. Life Sci. 2007; 64: 2771-2789.